Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Sep;30(9):1773-1776.
doi: 10.1681/ASN.2019050550. Epub 2019 Aug 16.

Authors' Reply

Yusuke Sakaguchi  1 , Takayuki Hamano  2 , Atsushi Wada  1 , Ikuto Masakane  1
Affiliations
Comment

Authors' Reply

Yusuke Sakaguchi et al. J Am Soc Nephrol. 2019 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Higher doses of ESA are prescribed for patients taking DPO-α (i.e., category 4 and 5) compared with those taking EPO-α/β. The range of ESA doses in each category is based on the dose conversion ratio (EPO/DPO=200).
Figure 2.
Figure 2.
Mortality rates are elevated in patients treated with DPO-α except for those in ESA dose category 1. The Cox proportional hazards model was adjusted for age, sex, body mass index, predialysis systolic BP, dialysis duration, dialysis vintage, single-pool Kt/V, diabetes mellitus, a history of cardiovascular diseases, laboratory data (albumin, urea nitrogen, C-reactive protein, hemoglobin, ferritin, albumin-adjusted calcium, phosphate, and parathyroid hormone), standardized erythropoietin resistance index, and facility indicators. The patients taking EPO-α/β in category 1 were treated as a reference group. The bar graph denotes the adjusted 2-year numbers needed to harm for all-cause death, which was calculated from the reciprocal of the adjusted absolute risk difference between patients taking EPO-α/β and those taking DPO-α in each ESA dose category. HR, hazard ratio; NNH, number needed to harm; Ref., reference.
See this image and copyright information in PMC

Comment on

References

    1. Rostoker G, Lepeytre F, Rottembourg J: Analysis of other confounding factors is mandatory before considering that long-acting erythropoiesis stimulating agents are deleterious to dialysis patients. J Am Soc Nephrol 30: 1771, 2019 - PMC - PubMed
    1. Sakaguchi Y, Hamano T, Wada A, Masakane I: Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol 30: 1037–1048, 2019 - PMC - PubMed
    1. Tanaka M, Shinohara K, Ono A, Ikuma M: ESA-resistance may be a potential confounder for mortality among different ESA types. J Am Soc Nephrol 30: 1772, 2019 - PMC - PubMed
    1. Hanafusa N, Tsuchiya K: Equivalent doses matters, rather than types. J Am Soc Nephrol 30: 1772, 2019 - PMC - PubMed
    1. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590, 1998 - PubMed

LinkOut - more resources